S100A2 is expressed in 37% of specimens of carcinoma in situ, and in <15% of breast cancer samples in vivo [63], suggesting that the loss of S100A2 is related to the development of breast cancer and does not appear to be with an early phase of tumor development. This evidence concerns the gene S100A2 and in situ carcinoma.